STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Zomedica Corp. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Zomedica Corp. (ZOMDF)2,126,959 stock appreciation rights with a conversion or exercise price of $0.1 per right. These rights become exercisable on 11/16/2026 and expire on 11/16/2035. Each right is linked to one share of common stock, so the transaction covers 2,126,959 underlying common shares. Following this grant, the director beneficially owns 2,126,959 derivative securities, held directly.

Positive
  • None.
Negative
  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rowe Jeffrey M

(Last) (First) (Middle)
1101 TECHNOLOGY DRIVE, STE 100

(Street)
ANN ARBOR MI 48108

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Right $0.1 11/17/2025 A 2,126,959 11/16/2026 11/16/2035 Common 2,126,959 $0 2,126,959 D
Explanation of Responses:
/s/ Jeffrey Rowe 11/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zomedica (ZOMDF) report in this Form 4?

A Zomedica director reported acquiring 2,126,959 stock appreciation rights tied to the company’s common stock on 11/17/2025.

What is the exercise price of the Zomedica (ZOMDF) stock appreciation rights?

The stock appreciation rights have a conversion or exercise price of $0.1 per right.

When do the Zomedica (ZOMDF) stock appreciation rights become exercisable and when do they expire?

The rights become exercisable on 11/16/2026 and have an expiration date of 11/16/2035.

How many Zomedica (ZOMDF) common shares underlie the reported derivative securities?

The grant covers 2,126,959 underlying common shares, matching the number of stock appreciation rights acquired.

What is the director’s beneficial ownership after this Zomedica (ZOMDF) transaction?

After the reported transaction, the director beneficially owns 2,126,959 derivative securities, held in direct ownership form.

Was this Zomedica (ZOMDF) Form 4 filed for one or multiple reporting persons?

The Form 4 was indicated as filed by one reporting person, not a group.

Zomedica Corp

OTC:ZOMDF

ZOMDF Rankings

ZOMDF Latest News

ZOMDF Latest SEC Filings

ZOMDF Stock Data

112.69M
954.19M
2.5%
0.55%
4.63%
Medical Devices
Healthcare
Link
United States
Ann Arbor